Find your next quality investment with Simply Wall St’s easy and powerful screener, trusted by over 7 million individual investors worldwide.
Sanofi (ENXTPA:SAN) has appointed Belén Garijo as its new Chief Executive Officer.
Garijo is set to replace current CEO Paul Hudson, marking a major leadership transition.
She returns to Sanofi after senior roles at Merck KGaA, with a focus on R&D, productivity, and governance.
Sanofi, one of Europe’s large pharmaceutical groups, sits at the intersection of prescription medicines, vaccines, and specialty care. Leadership changes at a company of this size can influence priorities across its pipeline, cost base, and geographic focus. For you as an investor following ENXTPA:SAN, this move is primarily about who sets those priorities over the coming years.
Garijo’s appointment signals attention on research productivity, operational efficiency, and corporate governance. As the new CEO settles in, investors will be watching for any updates to capital allocation, R&D focus areas, and portfolio decisions. The key question is how quickly her leadership agenda translates into concrete actions that affect Sanofi’s risk profile and strategic options.
Stay updated on the most important news stories for Sanofi by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Sanofi.
ENXTPA:SAN 1-Year Stock Price Chart
Quick Assessment
✅ Price vs Analyst Target: At €78.13 against a consensus target of €98.70, the price sits about 26% below where analysts think it could be.
✅ Simply Wall St Valuation: Simply Wall St currently assesses the shares as trading about 75.1% below its estimated fair value.
❌ Recent Momentum: The stock has posted a 3.3% decline over the past 30 days.
There is only one way to know the right time to buy, sell or hold Sanofi: head to Simply Wall St’s company report for the latest analysis of Sanofi’s fair value.
Key Considerations
📊 A new CEO with a track record in R&D and productivity may shift how Sanofi balances its pipeline, costs, and returns to shareholders.
📊 Watch for early messages on capital allocation, R&D priorities, and any refresh of long term financial targets under Garijo.
⚠️ Dividend coverage and the presence of large one off items in results are already flagged risks, so investors may want to see how the new leadership addresses these.
Dig Deeper
For the full picture including more risks and rewards, check out the complete Sanofi analysis. Alternatively, you can check out the community page for Sanofi to see how other investors believe this latest news will impact the company’s narrative.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SAN.PA.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com